MX2017002803A - Coronavirus bovino atenuado y vacunas relacionadas. - Google Patents

Coronavirus bovino atenuado y vacunas relacionadas.

Info

Publication number
MX2017002803A
MX2017002803A MX2017002803A MX2017002803A MX2017002803A MX 2017002803 A MX2017002803 A MX 2017002803A MX 2017002803 A MX2017002803 A MX 2017002803A MX 2017002803 A MX2017002803 A MX 2017002803A MX 2017002803 A MX2017002803 A MX 2017002803A
Authority
MX
Mexico
Prior art keywords
vaccines
bovine coronavirus
attenuated bovine
related vaccines
compositions
Prior art date
Application number
MX2017002803A
Other languages
English (en)
Inventor
Terri Lee Wasmoen
M Peters Catherine
W Mellencamp Mark
Xue Wenzhi
Trigo Emilio
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2017002803A publication Critical patent/MX2017002803A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe aislados de coronavirus bovino atenuado, composiciones que comprenden estos aislados, y métodos para utilizar tales composiciones en vacunas, incluyendo en vacunas vivas; la presente invención además describe la administración de tales vacunas, incluyendo la administración intranasal de tales vacunas, para ayudar en la prevención de una enfermedad respiratoria causada por el coronavirus bovino.
MX2017002803A 2014-09-03 2015-09-02 Coronavirus bovino atenuado y vacunas relacionadas. MX2017002803A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045183P 2014-09-03 2014-09-03
US201462073263P 2014-10-31 2014-10-31
PCT/EP2015/070006 WO2016034610A1 (en) 2014-09-03 2015-09-02 Attenuated bovine coronavirus and related vaccines

Publications (1)

Publication Number Publication Date
MX2017002803A true MX2017002803A (es) 2017-06-09

Family

ID=54012224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002803A MX2017002803A (es) 2014-09-03 2015-09-02 Coronavirus bovino atenuado y vacunas relacionadas.

Country Status (9)

Country Link
US (1) US10434168B2 (es)
EP (1) EP3188750B1 (es)
AU (1) AU2015310932B2 (es)
BR (1) BR112017003462B1 (es)
CA (1) CA2957472C (es)
ES (1) ES2788393T3 (es)
HU (1) HUE049826T2 (es)
MX (1) MX2017002803A (es)
WO (1) WO2016034610A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694499C1 (ru) * 2018-01-16 2019-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для обнаружения генома возбудителя коронавирусной инфекции у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени
RU2694558C1 (ru) * 2018-01-16 2019-07-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ выявления генома возбудителя коронавирусной инфекции у крупного рогатого скота
KR102089655B1 (ko) * 2018-08-17 2020-03-16 전남대학교 산학협력단 소 코로나바이러스 감염증 예방용 kwd20v-102 주의 약독화 생백신 조성물
WO2021045870A1 (en) * 2019-09-06 2021-03-11 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
RU2740097C1 (ru) * 2020-08-11 2021-01-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ выявления генома возбудителя коронавирусной инфекции нового типа (nCov19) у приматов
RU2741887C1 (ru) * 2020-08-11 2021-01-29 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для выявления генома возбудителя коронавирусной инфекции нового типа (nCov19) у приматов
AU2022208375A1 (en) * 2021-01-14 2023-07-13 Charles J. PIVEN Cytolytic t cell immunotherapy for highly pathogenic coronaviruses
WO2023038961A2 (en) * 2021-09-08 2023-03-16 La Jolla Institute For Immunology Common cold coronavirus t cell epitopes, methods and uses thereof
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs
CN116559439A (zh) * 2023-04-24 2023-08-08 江苏省农业科学院 一种牛冠状病毒间接elisa抗体检测试剂盒及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873422A (en) * 1972-10-30 1975-03-25 Univ Nebraska Vaccine for neonatal calf diarrhea
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
BR9808226A (pt) 1997-03-10 2000-05-16 Bayer Ag Coronavìrus respiratório bovino como uma vacina
WO1999015670A1 (en) 1997-09-25 1999-04-01 Biotechnology Research And Development Corporation LKTA DELETION MUTANT OF $i(P. HAEMOLYTICA)
US6974577B2 (en) 2001-02-04 2005-12-13 Novartris Ag Inactivated bovine scours vaccines, processes and method of preventing bovine scours
NZ543771A (en) 2003-07-02 2008-05-30 Biotechnology Res & Dev Acapsular Pasteurella multocida hyae deletion mutants
EP1533370A1 (en) * 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
US8440203B2 (en) 2009-11-06 2013-05-14 Intervet Inc. Methods of immunizing pregnant heifers at three months of gestation
DK3106176T3 (en) * 2011-12-06 2018-01-08 Valneva Austria Gmbh ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable

Also Published As

Publication number Publication date
BR112017003462B1 (pt) 2023-02-14
HUE049826T2 (hu) 2020-10-28
CA2957472A1 (en) 2016-03-10
ES2788393T3 (es) 2020-10-21
EP3188750B1 (en) 2020-03-11
US20170274065A1 (en) 2017-09-28
CA2957472C (en) 2021-10-26
AU2015310932A1 (en) 2017-03-09
WO2016034610A1 (en) 2016-03-10
EP3188750A1 (en) 2017-07-12
US10434168B2 (en) 2019-10-08
AU2015310932B2 (en) 2018-11-22
BR112017003462A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2016016722A (es) Coronavirus.
GB2541571A (en) Pharmaceutical compositions
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
PH12016501968A1 (en) Novel macrocyclic compounds
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
MY191539A (en) Streptococcal vaccine
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX2019005102A (es) Poxvirus quimericos sinteticos.
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
GB2556002B (en) Methods and compositions for nanoemulsion vaccine formulations
IN2014CH00840A (es)
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201790544A1 (ru) Композиция, содержащая гликопирролат, способ и устройство
NZ721832A (en) Solid forms of tenofovir